Endocrine Abstracts

The pharmacologic armamentarium available to clinicians to reduce fracture risk in women with postmenopausal osteoporosis consists essentially of antiresorptive agent. Recently, peptides from the parathyroid hormone (PTH) family, which under specific modalities of administration act as anabolic agents have become available. The interest generated by these alternatives to antiresorptive treatment resides in their greater potential for restauration of bone mass and possibly also...

Objective: The Swiss Primary HyperParaThyroidism (PHPT) Cohort Study is an ongoing, prospective, non-interventional project collecting clinical, densitometric, biochemical and outcome data in patients with PHPT. The aims are to describe the profile of these patients particularly neurobehavioral and cognitive symptoms, changes in calcium and PTH over time and treatment modalities.Methods: Patients newly diagnosed with PHPT and with high serum calcium leve...